Risk factors for the development and outcome of prosthetic valve endocarditis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prosthetic valve endocarditis (PVE) was encountered in 20 out of 821 patients (2.4%) who underwent valve replacement between 1 January 1981 and 30 June 1985. At a follow-up time 6-60 months later the actuarial risk of PVE was 1% yr-1. The incidence of PVE was higher after bioprosthetic replacement (5%), after aortic valve replacement (3.4%) and in patients operated on for antecedent endocarditis of either the native or the prosthetic valve (10%). The overall mortality was 40%. Surgical treatment improved changes of survival (27% mortality) compared to medical treatment (80% mortality) independently of other factors (bioprosthesis or mechanical prosthesis, aortic or mitral position, early or late onset PVE).

Original languageEnglish
Pages (from-to)371-374
Number of pages4
JournalEuropean Heart Journal
Volume8
Issue numberSUPPL. J
Publication statusPublished - 1987

Fingerprint

Endocarditis
Mortality
Bioprosthesis
Aortic Valve
Prostheses and Implants
Survival
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Risk factors for the development and outcome of prosthetic valve endocarditis. / Lengyel, M.

In: European Heart Journal, Vol. 8, No. SUPPL. J, 1987, p. 371-374.

Research output: Contribution to journalArticle

@article{ed313925bcc7401cb07d05faa91a33a0,
title = "Risk factors for the development and outcome of prosthetic valve endocarditis",
abstract = "Prosthetic valve endocarditis (PVE) was encountered in 20 out of 821 patients (2.4{\%}) who underwent valve replacement between 1 January 1981 and 30 June 1985. At a follow-up time 6-60 months later the actuarial risk of PVE was 1{\%} yr-1. The incidence of PVE was higher after bioprosthetic replacement (5{\%}), after aortic valve replacement (3.4{\%}) and in patients operated on for antecedent endocarditis of either the native or the prosthetic valve (10{\%}). The overall mortality was 40{\%}. Surgical treatment improved changes of survival (27{\%} mortality) compared to medical treatment (80{\%} mortality) independently of other factors (bioprosthesis or mechanical prosthesis, aortic or mitral position, early or late onset PVE).",
author = "M. Lengyel",
year = "1987",
language = "English",
volume = "8",
pages = "371--374",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "SUPPL. J",

}

TY - JOUR

T1 - Risk factors for the development and outcome of prosthetic valve endocarditis

AU - Lengyel, M.

PY - 1987

Y1 - 1987

N2 - Prosthetic valve endocarditis (PVE) was encountered in 20 out of 821 patients (2.4%) who underwent valve replacement between 1 January 1981 and 30 June 1985. At a follow-up time 6-60 months later the actuarial risk of PVE was 1% yr-1. The incidence of PVE was higher after bioprosthetic replacement (5%), after aortic valve replacement (3.4%) and in patients operated on for antecedent endocarditis of either the native or the prosthetic valve (10%). The overall mortality was 40%. Surgical treatment improved changes of survival (27% mortality) compared to medical treatment (80% mortality) independently of other factors (bioprosthesis or mechanical prosthesis, aortic or mitral position, early or late onset PVE).

AB - Prosthetic valve endocarditis (PVE) was encountered in 20 out of 821 patients (2.4%) who underwent valve replacement between 1 January 1981 and 30 June 1985. At a follow-up time 6-60 months later the actuarial risk of PVE was 1% yr-1. The incidence of PVE was higher after bioprosthetic replacement (5%), after aortic valve replacement (3.4%) and in patients operated on for antecedent endocarditis of either the native or the prosthetic valve (10%). The overall mortality was 40%. Surgical treatment improved changes of survival (27% mortality) compared to medical treatment (80% mortality) independently of other factors (bioprosthesis or mechanical prosthesis, aortic or mitral position, early or late onset PVE).

UR - http://www.scopus.com/inward/record.url?scp=0023552797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023552797&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023552797

VL - 8

SP - 371

EP - 374

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - SUPPL. J

ER -